ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
Concord Drugs Limited is notifying shareholders about the annual report web-link as per Regulation 36(1)(b). Shareholders are urged to update their email addresses.
Concord Drugs Ltd submitted its quarterly shareholding pattern for the period ended June 30, 2026, pursuant to SEBI Regulation 31(1)(b). This is a routine periodic disclosure.
Concord Drugs Ltd filed its quarterly shareholding pattern for the period ended June 30, 2026, as required under SEBI regulations.
Concord Drugs Limited filed its Annual Secretarial Compliance Report for the year ended March 31, 2026. The report notes minor delays in certain regulatory submissions.
Concord Drugs Limited confirmed it does not fall under the 'Large Corporate' category for the financial year ended March 31, 2026. Consequently, the company is not subject to the fund-raising requirements or annual disclosure obligations mandated by SEBI for Large Corporates. The company reported zero outstanding borrowings as of the specified date.